Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study

Epidermal growth factor receptor (EGFR) mutations for EGFR-tyrosine kinase inhibitors (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are with clinical benefits. Nevertheless, eventual resistance to EGFR-TKI is almost inevitable. In about 50% patients, EGFR-TKI develops a secondary mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuli, Wei, Yuan, Ma, Xiaoping, Ma, Xinyu, Gong, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076133/
https://www.ncbi.nlm.nih.gov/pubmed/29995771
http://dx.doi.org/10.1097/MD.0000000000011346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076133/
https://www.ncbi.nlm.nih.gov/pubmed/29995771
http://dx.doi.org/10.1097/MD.0000000000011346

Ejemplares similares